Clinical Trials & Pharma Engagement: • Worked with @biovie.bsky.social on study design & recruitment for their Bezisterim trial for #LongCovid, an investigational drug that has shown promise in neurodegenerative conditions. /5

Our CEO, Cuong Do, spoke with @charlespiller.bsky.social about patterns of alleged misconduct at certain South Florida clinical trial sites, and the devastating implications for the Alzheimer’s community- from patients & families to researchers & drug developers seeking to make a difference.

Enrollment is complete in our Phase 2 SUNRISE-PD clinical trial evaluating bezisterim for the treatment of motor & non-motor symptoms in patients with early-stage #Parkinson’s disease. Topline results expected in 1H 2026. Learn more: investors.bioviepharma.com/news/news-de... #Neurology #BIVI

A study published in @natimmunol.nature.com provides additional evidence that #LongCOVID is associated with chronic #inflammation & metabolic dysregulation. The findings align w/ the MoA of bezisterim, which targets upstream immune signaling involved in chronic inflammation. #BrainFog #Fatigue

Our CEO, Cuong Do, provided an update on the company’s lead candidate bezisterim currently in clinical trials for patients with #Parkinsons’s & #longCOVID. Learn about clinical & regulatory catalysts in 2026 www.youtube.com/watch?v=_RI6... #Neuroinflammation #InsulinResistance #Neuroscience

On a recent episode of Power to the Patients, our CMO Dr. Joseph Palumbo discussed why #inflammation is emerging as a critical factor in treating #neurodegenerative diseases like #Alzheimer's & #Parkinson's. Listen here: www.youtube.com/watch?v=LNXV... #Neuroscience #InsulinResistance #LongCOVID

On a recent episode of Power to the Patients podcast, our CEO Cuong Do shares how BioVie is focused on the role of #inflammation & #insulinresistance, key drivers of #Alzheimer’s, #Parkinson’s, & #LongCOVID. Listen here: bit.ly/3Kdr6nE Watch: lnkd.in/gCxPufWc #ClinicalTrials

BioVie is proud to announce that our CFO Wendy Kim was selected as a winner of the Third Annual Women CFOs of the Year Awards by the @feisv.bsky.social chapter honoring outstanding finance leaders for their achievements. bit.ly/4rBiQP3 #LifeSciences #BiotechLeadership

This month we honor those living with #Alzheimer’s and the families, clinicians, & researchers supporting them. And THANK YOU to the millions of #caregivers providing essential, heartfelt assistance to loved ones with #neurodegenerative disorders. #AlzheimersDiseaseAwareness #FamilyCaregiversMonth

We’re at #LongCOVIDIntl 2025 presenting our ongoing P2 ADDRESS-LC trial evaluating the efficacy, safety, & tolerability of bezisterim in participants with #LongCOVID enriched for #BrainFog & #fatigue. Learn about the currently enrolling trial: www.addresslongcovid.com @academicmededu.bsky.social

Earlier this month our CEO held a virtual investor webinar to discuss bezisterim for the treatment of neurological & neurodegenerative diseases. Catch the replay here: www.youtube.com/watch?v=ts_1... #Inflammation #InsulinResistance #Alzheimers #Parkinsons #LongCOVID $BIVI

Dr. Chris Reading, SVP of our Alzheimer’s program, presented at Longevity Biotech 2025 in Boston. He discussed bezisterim’s multifaceted MoA, targeting #inflammation & #insulinresistance in the brain, 2 key drivers of #neurodegenerative disease. #Longevity #Biotech #Aging #AlzheimersDisease

A reminder to join us tomorrow for a live webinar with our CEO, Cuong Do, discussing bezisterim for the treatment of neurological & neurodegenerative diseases. Register here: investors.bioviepharma.com/news/news-de... #Inflammation #InsulinResistance #Alzheimers #Parkinsons #LongCOVID

Our CEO, Cuong Do, will share updates on bezisterim for the treatment of neurological & neurodegenerative diseases during a live webinar on October 8. Register here: investors.bioviepharma.com/news/news-de... #Neuroinflammation #InsulinResistance #Alzheimers #Parkinsons #LongCOVID #NeuroSky

On #WorldAlzheimersDay, we recognize the nearly 60M people worldwide living w/ Alzheimer’s & other forms of dementia. We're committed to advancing the science of #neuroinflammation -a root cause of #Alzheimer’s, #Parkinson’s & other diseases of #aging. #InsulinResistance #BIVI

Our CEO, Cuong Do, recently joined Kevin McCullough to share an update on the clinical trials of bezisterim for patients with #Parkinson’s disease & #LongCOVID. Listen here: podcasts.apple.com/us/podcast/t... #Neuroinflammation #InsulinResistance #Aging #ClinicalTrials #Neurology #Neurosky #BIVI

We presented the ADDRESS-LC P2 trial design of our ongoing study exploring bezisterim to treat #neurological symptoms at the #LongCOVID @keystonesymposia.bsky.social. Learn more: investors.bioviepharma.com/news/news-de... #BrainFog #Fatigue #Neuroinflammation #KSLongCOVID26

The role of neuroinflammation is no longer considered a peripheral component in the treatment of #Parkinson’s disease. It is central… and offers a new array of therapeutic promise. @parkinsondotorg.bsky.social @gohealio.bsky.social #Neuroinflammation #InsulinResistance #Neurology #Neurosky

If you missed @solveme.bsky.social's webinar on the ADDRESS-LC #ClinicalTrial studying the impact of bezisterim on #BrainFog and #Fatigue in #LongCovid, watch the replay here: www.youtube.com/watch?v=-mMg... #Neuroinflammation #Neurology #Neurosky

BioVie was a poster winner at this year’s #ATMRD2025. Our and lead author spoke with @neurologylive.bsky.social about the presentation. Watch here: www.neurologylive.com/view/designi... #ParkinsonsDisease #ClinicalTrials #Neuroinflammation #Neurology #Neurosky

We presented data that suggest bezisterim’s potential to target epigenetic-driven age deceleration as a treatment for #Alzheimers disease and other #neurodegenerative diseases of aging. Learn more: investors.bioviepharma.com/news/news-de... #Aging #Longevitiy #Neuroscience #Neurosky #BIVI

We’re thrilled to announce the appointment of Amy S. Chappell, MD, FAAN, and Kameel D. Farag to our Board of Directors. Details: investors.bioviepharma.com/news/news-de... #Biotech #Neuroinflammation #Neurology #BIVI

Register today for our webinar “The ADDRESS-LC Trial: Studying the Impact of Bezisterim on Brain Fog and Fatigue in People with #LongCovid.” Sign up here: us02web.zoom.us/webinar/regi...

In a keynote session today at #ARC2025, we presented data highlighting bezisterim’s potential to target epigenetic-driven age acceleration as a treatment for #Alzheimers and other #neurodegenerative diseases of aging. Learn more here: investors.bioviepharma.com/news/news-de... #Neurosky #BIVI

Dr. Mark Stacy highlighted the potential of bezisterim as a treatment targeting #neuroinflammation in Parkinson's disease & its innovative P2 trial design on Practical Neurology's podcast. Listen here: practicalneurology.com/diseases-dia... #ParkinsonsAwareness #BrainHealthMonth #Neurology #BIVI

Our hybrid, decentralized trial of bezisterim (NE3107) in early Parkinson’s Disease prioritizes patient access and participation. Learn more: investors.bioviepharma.com/news/news-de... #ATMRD #ParkinsonsDisease #MovementDisorders #Neurology #BIVI

We will be presenting a poster at #ATMRD highlighting the decentralized design of our Phase 2 SUNRISE-PD clinical trial evaluating bezisterim (NE3107) in early Parkinson’s disease. Learn more: investors.bioviepharma.com/news/news-de... #ParkinsonsDisease #MovementDisorders #Neurology #Medsky

A new #LongCovid clinical trial is enrolling for bezisterim, an investigational anti-inflammatory drug that crosses the blood-brain barrier. It has been studied in neurological & neurodegenerative disorders, including Alzheimer’s & Parkinson’s. 1/

#LongCOVID neurological symptoms – brain fog, memory loss, fatigue – mirror those of Alzheimer’s & Parkinson’s. The link? Chronic neuroinflammation. Shared pathways suggest post-viral syndromes may accelerate age-related neurodegeneration.

June is Alzheimer’s & Brain Health Awareness Month, a time to spotlight not only Alzheimer’s but also the broader challenges facing brain health, including Parkinson’s disease. Learn more at www.sunrisePD.com/ #ParkinsonsAwareness #BrainHealthMonth #neurosci #neuroskyence #Neurology

Last week we held a virtual KOL event with two leading experts in the field to discuss the unmet need in #ParkinsonsDisease along with an overview of our currently enrolling SUNRISE-PD trial in newly diagnosed patients. Catch the replay here: lifescievents.com/event/biovie... #BIVI #Neuroscience

Alzheimer’s disease is the 7th leading cause of death globally – yet, despite decades of effort, there are significant gaps in the fight to #ENDALZ. We’re joining @alzassociation.bsky.social this month in raising awareness. Learn more: www.alz.org/abam/overvie... #AlzheimersAwareness #BrainHealth

REMINDER: Join us today at 12pm EDT for a virtual event to learn more about the urgent unmet needs and treatment landscape in #ParkinsonsDisease and our ongoing SUNRISE-PD clinical trial in newly diagnosed patients. Register here: lifescievents.com/event/biovie... #Medsky #Neurosky #ClinicalTrials

We're leading the charge in targeting #neuroinflammation - a root cause of Alzheimer’s, Parkinson’s & long COVID. Cuong Do, BioVie's CEO, joins The Longevity Formula podcast to discuss BioVie’s novel approach with bezisterim. Listen: podcasts.apple.com/us/podcast/t... #Medsky #Aging #Longevity

Enrollment is open for our SUNRISE-PD clinical trial in patients who have been diagnosed with #ParkinsonsDisease disease but have not been prescribed carbidopa/levodopa. Patients who qualify can participate from home or at a registered clinic. Learn more: sunrisePD.com #Medsky #Neurosky